Robert Zeiser
Principal Investigator
Department of Hematology, Oncology and Stem-Cell Transplantation
Medical Center University of Freiburg
Hugstetter Straße 55
79106 Freiburg i. Brsg.
- +49 761 / 270 – 34580
- robert.zeiser@uniklinik-freiburg.de
- Homepage
Current position
Academic training
| 1995 – 2001 | Medical School, Albert-Ludwigs-Universität Freiburg |
Advanced academic qualifications
| 2010 | Habilitation for Internal Medicine, subject: Regulation of allogeneic T cell responses, Albert-Ludwigs-Universität Freiburg |
| 2001 | Doctorate, Department of Pathology, Albert-Ludwigs Universität Freiburg |
Postgraduate positions
| Since 2019 | Director (Abteilungsleiter) Division of Tumor immunology |
| Since 2016 | Section Head of Tumor immunology within Internal Medicine I |
| Since 2013 | W3-Professor, Medical Faculty, Albert-Ludwigs Universität Freiburg |
| Since 2010 | Attending physician, University Medical Center Freiburg |
| Since 2007 | Head of the Laboratory for Tumor immunology and Immune modulation |
| 2005 – 2007 | Postdoctoral Research Fellow at the Department of BMT at Stanford University, Stanford, USA |
| 2001 – 2004 | Residency and Fellowship in Medicine, Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center University of Freiburg |
Miscellaneous (Honors, Awards)
| 2021 | Deutscher Krebspreis (German Cancer Award) |
| 2020 | Preis der Berlin-Brandenburgischen Akademie der Wissenschaften |
| 2019 | Paul Martini Award (Paul Martini Foundation) |
| 2017 | Richtzenhain Cancer Research Award (DKFZ) |
| 2016 | ERC Consolidator grant (EU) |
| 2015 | Jon van Rood Award (European Soc. for Blood & Marrow Transplantation) |
| 2014 | Artur Pappenheim Award (Dt. Gesellschaft für Hämatologie/Onkologie) |
| 2013 | Heisenberg Professorship (Deutsche Forschungsgemeinschaft) |
| 2011 | Theodor Frerichs Award (Deutsche Gesellschaft für Innere Medizin) |
| 2007 | BBMT Editorial award for the best publication in 2007 (ASBMT) |
| 2006 | Scholar Award (American Society of Hematology) |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Brummer T, Zeiser R. The role of the MDM2/p53 axis in anti-tumor immune responses. Blood. 2023 Jul 19:blood.2023020731. doi: 10.1182/blood.2023020731. Epub ahead of print.
Fetsch V, Zeiser R. Chimeric antigen receptor T cells for acute myeloid leukemia. Eur J Haematol. 2023 Jul 16. doi: 10.1111/ejh.14047. Epub ahead of print.
de Maissin H, Groß PR, Mohiuddin O, Weigt M, Nagel L, Herzog M, Wang Z, Willing R, Reichardt W, Pichotka M, Heß L, Reinheckel T, Jessen HJ, Zeiser R, Bock M, von Elverfeldt D, Zaitsev M, Korchak S, Glöggler S, Hövener JB, Chekmenev EY, Schilling F, Knecht S, Schmidt AB. In Vivo Metabolic Imaging of [1-13C]Pyruvate-d3 Hyperpolarized By Reversible Exchange With Parahydrogen. Angew Chem Int Ed Engl. 2023 Jul 13:e202306654. doi: 10.1002/anie.202306654. Epub ahead of print.
Zeiser R, Prinz M. Immune checkpoint inhibitor induced neurocognitive deficits in patients. Brain Commun. 2023 Jun 20;5(3):fcad186. doi: 10.1093/braincomms/fcad186.
Wenger V, Zeiser R. Editorial: Current concepts of cellular and biological drugs to modulate regulatory T cell activity in the clinic, volume II. Front Immunol. 2023 Jun 13;14:1221904. doi: 10.3389/fimmu.2023.1221904.
Langhammer M, Schöpf J, Jaquet T, Horn K, Angel M, Spohr C, Christen D, Uhl FM, Maié T, Jacobi H, Feyerabend TB, Huber J, Panning M, Sitaru C, Costa I, Zeiser R, Aumann K, Becker H, Braunschweig T, Koschmieder S, Shoumariyeh K, Huber M, Schemionek-Reinders M, Brummer T, Halbach S. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model. Leukemia. 2023 May 9. doi: 10.1038/s41375-023-01916-x. Online ahead of print.
Zeiser R, Chen YB, Youssef NN, Ayuk F. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2. Br J Haematol. 2023 May;201(4):620-627. 2023. doi: 10.1111/bjh.18778.
Langenbach M, Giesler S, Richtsfeld S, da Costa-Pereira S, Rindlisbacher L, Wertheimer T, Braun LM, Andrieux G, Duquesne S, Pfeifer D, Woessner NM, Menssen HD, Taromi S, Duyster J, Boerries M, Brummer T, Blazar BR, Minguet S, Turko P, Levesque MP, Becher B, Zeiser R. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production. Mol Cancer Res. 2023 Apr 18:MCR-22-0898. doi: 10.1158/1541-7786.MCR-22-0898. Epub ahead of print.
Edwards-Hicks J, Apostolova P, Buescher JM, Maib H, Stanczak MA, Corrado M, Klein Geltink RI, Maccari ME, Villa M, Carrizo GE, Sanin DE, Baixauli F, Kelly B, Curtis JD, Haessler F, Patterson A, Field CS, Caputa G, Kyle RL, Soballa M, Cha M, Paul H, Martin J, Grzes KM, Flachsmann L, Mitterer M, Zhao L, Winkler F, Rafei-Shamsabadi DA, Meiss F, Bengsch B, Zeiser R, Puleston DJ, O’Sullivan D, Pearce EJ, Pearce EL. Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function. Nat Immunol. 2023 Mar;24(3):516-530. doi: 10.1038/s41590-023-01419-y. Epub 2023 Feb 2.
Socie G, Niederwieser D, von Bubnoff N, Mohty M, Szer J, Or R, Garrett J, Prahallad AC, Wilke C, Zeiser R. Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis. Blood. 2023 Feb 24:blood.2022018579. doi: 10.1182/blood.2022018579.
Zeiser R. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2023 Feb 17:JCO2202256. doi: 10.1200/JCO.22.02256.
Jaeger A, Gambheer SMM, Sun X, Chernyakov D, Skorobohatko O, Mack TM, Kissel S, Pfeifer D, Zeiser R, Fisch P, Andrieux G, Bräuer-Hartmann D, Bauer M, Schulze S, Follo M, Boerries M, von Bubnoff N, Miething C, Hidalgo JV, Klein C, Weber T, Wickenhauser C, Binder M, Dierks C. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023 Jan 25:blood.2022015653. doi: 10.1182/blood.2022015653.
Rückert T, Andrieux G, Boerries M, Hanke-Müller K, Woessner NM, Doetsch S, Schell C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S, Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J, Zeiser R, Köhler N. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med. 2022 Dec 21;14(676):eabp9675. doi: 10.1126/scitranslmed.abp9675. Epub 2022 Dec 21. PMID: 36542690.
free full text: https://www.science.org/stoken/author-tokens/ST-951/full
Grüninger PK, Uhl F, Herzog H, Gentile G, Andrade-Martinez M, Schmidt T, Han K, Morgens DW, Bassik MC, Cleary ML, Gorka O, Zeiser R, Groß O, Duque-Afonso J. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia. Cancer Gene Ther. 2022 Nov;29(11):1751-1760. doi: 10.1038/s41417-022-00491-0.
Biavasco F, Ihorst G, Wäsch R, Wehr C, Bertz H, Finke J, Zeiser R. Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. Bone Marrow Transplant. 2022 Oct;57(10):1500-1506. doi: 10.1038/s41409-022-01741-3.
Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Núñez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, Rückert T, Märklin M, Holzmayer S, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, Köhler N, Duyster J, Menssen HD, Boerries M, Buescher JM, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce EL, Becher B, Zeiser R. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood. 2022 Sep 8;140(10):1167-1181. doi: 10.1182/blood.2022016082.
Highlighted by this Editorial: Bleakley M, Biernacki M. MDM2 inhibition augments GVL effect. Blood. 2022 Sep 8;140(10):1064-1065. doi: 10.1182/blood.2022017724. PMID: 36074535.
Zeiser R, Warnatz K, Rosshart S, Sagar, Tanriver Y. GVHD, IBD and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunity. Eur J Immunol. 2022 Sep;52(9):1406-1418. doi: 10.1002/eji.202149530.
Biavasco F, Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022 Sep;116(3):341-350. doi: 10.1007/s12185-022-03352-6.
Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Front Oncol. 2022 Jul 27;12:931774. doi: 10.3389/fonc.2022.931774.
Haring E, Andrieux G, Uhl FM, Krausz M, Proietti M, Sauer B, Esser PR, Martin SF, Pfeifer D, Schmitt-Graeff A, Duyster J, Köhler N, Grimbacher B, Boerries M, Aumann K, Zeiser R, Apostolova P. Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease. Haematologica. 2022 Jul 1;107(7):1538-1554. doi: 10.3324/haematol.2021.278387.
Köhler N, Zeiser R. Epigenetic Regulation to Enhance Graft-versus-Leukemia Activity. Cancer Discov. 2022 Jun 2;12(6):1410-1412.
Zeiser R, Lee SJ. Three FDA-approved therapies for chronic GVHD. Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448.
Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CP, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJ, Meyers G, Ghosh M, Deeren D, Sanz J, Morariu-Zamfir R, Arbushites M, Lakshminarayanan M, Barbour AM, Chen YB. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022 Jan;9(1):e14-e25.doi: 10.1016/S2352-3026(21)00367-7.
highlighted by this Editorial: Paczesny S. Graft-versus-host disease treatment beyond corticosteroids in newly diagnosed patients? Lancet Haematol. 2022 Jan;9(1):e2-e3. doi: 10.1016/S2352-3026(21)00376-8. PMID: 34971578.
Zeiser R, Teshima T. Non-classical manifestations of acute GVHD. Blood. 2021 Dec 2;138(22):2165-2172. doi: 10.1182/blood.2021012431.
Braun LM, Zeiser R. Kinase Inhibition as Treatment for Acute and Chronic Graft- Versus-Host Disease. Front Immunol. 2021 Nov 17;12:760199. doi: 10.3389/fimmu.2021.760199.
El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021 Nov 8;12(1):6436. doi: 10.1038/s41467-021-26683-0.
Vinnakota JM, Zeiser R. Acute Graft- Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System. Front Immunol. 2021 Oct 6;12:748019. doi: 10.3389/fimmu.2021.748019.
Contact
